Additionally, given that the APOE ε2 allele is associated with decreased risk of late-onset AD and has been shown to modulate the immune response of microglia, therapeutic strategies aimed at mimicking the protective effects of the APOE ε2 allele are now being considered as disease-modifying interventions for AD [320]. Here, APOE is linked to Alzheimer disease.